INCY 250516 65.00C(INCY250516C65000) Stock Price Today

US OptionsDetailed Quotes

INCY250516C65000

Watchlist

0.60
-0.08-11.76%

15min DelayTrading Apr 24 14:48 ET

0.60High0.60Low

Intraday

5D
Daily

News

Earnings Preview: Incyte to Report Financial Results Pre-market on April 29
Moomoo NewsApr 23 21:00 ET
J.P. Morgan Maintains Incyte(INCY.US) With Hold Rating, Announces Target Price $68
Moomoo NewsApr 21 19:31 ET · Ratings
Incyte Is Maintained at Neutral by JP Morgan
Dow JonesApr 21 13:25 ET · Ratings
Incyte Analyst Ratings
BenzingaApr 21 13:14 ET · Ratings
JPMorgan Adjusts Incyte Price Target to $68 From $70, Maintains Neutral Rating
MT NewswiresApr 21 08:02 ET · Ratings
BofA Securities Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $87
Moomoo NewsApr 20 19:31 ET · Ratings

Comments

Jerry Kronenberg

Mar 18 04:27

Columns Wall Street Today: DJIA, S&P 500 and Nasdaq Composite All End in the Green on St. Patrick's Day

The Dow Jones Industrial Average, S&P 500 and Nasdaq Composite all ended in the green Monday for St. Patrick's Day, rising for a second straight session as markets continued to partially rebound from their recent tariff-induced sell-off.
The $Dow Jones Industrial Average (.DJI.US)$ led the way higher, gaining 353.45 points (0.9%) to end the day at 41.841.63. The $S&P 500 Index (.SPX.US)$ likewise added 3...

CPI data falls short of expectations: Is a market recovery in sight?

Teddy123

Mar 17 20:54

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa

$Incyte (INCY.US)$
Breakthrough: Dual Phase 3 Trials Prove Povorcitinib's Success in Treating Hidradenitis Suppurativa

Teddy123

Mar 8 22:56

Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura®) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting

$Incyte (INCY.US)$
Can Incyte's Opzelura Break Through in Prurigo Nodularis? Phase 3 Data Reveals Critical Insights

Teddy123

Mar 3 00:03

Incyte to Unveil New Data from its Dermatology Portfolio at 2025 American Academy of Dermatology (AAD) Annual Meeting

$Incyte (INCY.US)$
Can Incyte's New Clinical Data Revolutionize Prurigo Nodularis Treatment? AAD 2025 Reveals Answers

Teddy123

Feb 20 21:13

Incyte and Genesis Therapeutics Announce Strategic AI-focused Research Collaboration

$Incyte (INCY.US)$
AI Meets Drug Discovery: Inside Incyte's $620M Genesis Deal - Will This Transform Pharma R&D?